Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
James Bolognese
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Procedures
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
10
Ehrich, Elliot
7
Watson, Douglas
6
Simon, Thomas
6
Reicin, Alise
5
Seidenberg, BC
5
Quan, Hude
5
Krupa, David
5
Harper, SE
4
Curtis, Sean
3
Sperling, Rhoda
3
Zhao, PL
3
Daniels, B
3
Detora, Lisa
3
Gertz, Barry
3
Schnitzer, Thomas
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of James Bolognese (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2006: Curtis Sean P; Ko Amy T; Bolognese James A; Cavanaugh Paul F; Reicin Alise S
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Current medical research and opinion 2006;22(12):2365-74.
-
2006: Cannon Christopher P; Curtis Sean P; FitzGerald Garret A; Krum Henry; Kaur Amarjot; Bolognese James A; Reicin Alise S; Bombardier Claire; Weinblatt Michael E; van der Heijde Désirée; Erdmann Erland; Laine Loren;
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Lancet 2006;368(9549):1771-81.
-
2006: Cannon Christopher P; Curtis Sean P; Bolognese James A; Laine Loren;
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
American heart journal 2006;152(2):237-45.
-
2006: Reiff Andreas; Lovell Daniel J; Adelsberg Janet Van; Kiss Maria H B; Goodman Steven; Zavaler Manuel Ferrandiz; Chen Pei-Yun; Bolognese James A; Cavanaugh Paul; Reicin Alise S; Giannini Edward H
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
The Journal of rheumatology 2006;33(5):985-95.
-
2005: Ramey Dena R; Watson Douglas J; Yu Chang; Bolognese James A; Curtis Sean P; Reicin Alise S
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.
Current medical research and opinion 2005;21(5):715-22.
-
2004: Watson D J; Bolognese J A; Yu C; Krupa D; Curtis S
Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Current medical research and opinion 2004;20(12):1899-908.
-
2004: Watson Douglas J; Yu Qinfen; Bolognese James A; Reicin Alise S; Simon Thomas J
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Current medical research and opinion 2004;20(10):1539-48.
-
2003: Bolognese J A; Schnitzer T J; Ehrich E W
Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2003;11(7):499-507.
-
2002: Gertz Barry J; Krupa David; Bolognese James A; Sperling Rhoda S; Reicin Alise
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Current medical research and opinion 2002;18(2):82-91.
-
2001: Bolognese J A; Ehrich E W; Schnitzer T J
Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints.
The Journal of rheumatology 2001;28(12):2700-4.
-
2001: Watson D J; Harper S E; Zhao P L; Bolognese J A; Simon T J
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
MedGenMed : Medscape general medicine 2001;3(4):6.
-
2001: Detora L M; Krupa D; Bolognese J; Sperling R S; Ehrich E W
Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
The Journal of rheumatology 2001;28(11):2494-503.
-
2001: Hawkey C J; Laine L; Harper S E; Quan H U; Bolognese J A; Mortensen E;
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
Alimentary pharmacology & therapeutics 2001;15(10):1593-601.
-
2001: Ehrich E W; Bolognese J A; Watson D J; Kong S X
Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
The American journal of managed care 2001;7(6):609-16.
-
2001: Truitt K E; Sperling R S; Ettinger W H; Greenwald M; DeTora L; Zeng Q; Bolognese J; Ehrich E;
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.
Aging (Milan, Italy) 2001;13(2):112-21.
-
2000: Saag K; van der Heijde D; Fisher C; Samara A; DeTora L; Bolognese J; Sperling R; Daniels B
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group.
Archives of family medicine 2000;9(10):1124-34.
-
2000: Ehrich E W; Davies G M; Watson D J; Bolognese J A; Seidenberg B C; Bellamy N
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
The Journal of rheumatology 2000;27(11):2635-41.
-
2000: Watson D J; Harper S E; Zhao P L; Quan H; Bolognese J A; Simon T J
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Archives of internal medicine 2000;160(19):2998-3003.
-
2000: Hunt R H; Bowen B; Mortensen E R; Simon T J; James C; Cagliola A; Quan H; Bolognese J A
A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
The American journal of medicine 2000;109(3):201-6.
-
2000: Day R; Morrison B; Luza A; Castaneda O; Strusberg A; Nahir M; Helgetveit K B; Kress B; Daniels B; Bolognese J; Krupa D; Seidenberg B; Ehrich E
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
Archives of internal medicine 2000;160(12):1781-7.
-
2000: Cannon G W; Caldwell J R; Holt P; McLean B; Seidenberg B; Bolognese J; Ehrich E; Mukhopadhyay S; Daniels B
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
Arthritis and rheumatism 2000;43(5):978-87.
-
2000: Hawkey C; Laine L; Simon T; Beaulieu A; Maldonado-Cocco J; Acevedo E; Shahane A; Quan H; Bolognese J; Mortensen E
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
Arthritis and rheumatism 2000;43(2):370-7.
-
1999: Langman M J; Jensen D M; Watson D J; Harper S E; Zhao P L; Quan H; Bolognese J A; Simon T J
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
JAMA : the journal of the American Medical Association 1999;282(20):1929-33.
-
1999: Ehrich E W; Schnitzer T J; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz B J
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
The Journal of rheumatology 1999;26(11):2438-47.
-
1999: Schnitzer T J; Truitt K; Fleischmann R; Dalgin P; Block J; Zeng Q; Bolognese J; Seidenberg B; Ehrich E W
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.
Clinical therapeutics 1999;21(10):1688-702.
-
1999: Murphy M G; Bach M A; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz B J
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14(7):1182-8.
-
1999: Lanza F L; Rack M F; Simon T J; Quan H; Bolognese J A; Hoover M E; Wilson F R; Harper S E
Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
Alimentary pharmacology & therapeutics 1999;13(6):761-7.
-
1996: Girman C J; Kolman C; Liss C L; Bolognese J A; Binkowitz B S; Stoner E
Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group.
The Prostate 1996;29(2):83-90.
-
1996: Zhao P L; Nachbar R B; Bolognese J A; Chapman K
Two new criteria for choosing sample size in combinatorial chemistry.
Journal of medicinal chemistry 1996;39(2):350-2.
-
1995: Zhao P L; Zambias R; Bolognese J A; Boulton D; Chapman K
Sample size determination in combinatorial chemistry.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(22):10212-6.
-
1992: Bolognese J A; Kozloff R C; Kunitz S C; Grino P B; Patrick D L; Stoner E
Validation of a symptoms questionnaire for benign prostatic hyperplasia.
The Prostate 1992;21(3):247-54.
Sign-in to see more
